News Release

Plasma cell-CD8+ T-cell co-enrichment marks an immune-responsive hepatocellular carcinoma subtype

Peer-Reviewed Publication

First Hospital of Jilin University

Visual Abstract

image: 

Visual Abstract

view more 

Credit: By Aryan Neupane, Anuradha Budhu, Farid Rashidi Mehrabadi, et al.

Key messages

  • Molecular profiling identified two hepatocellular carcinoma subtypes that were not significantly associated with racial classification, suggesting that they primarily capture tumour-intrinsic biological heterogeneity.
  • The immune-enriched RC2 subtype was characterised by tertiary lymphoid structure enrichment and coordinated plasma cell-CD8+ T-cell infiltration.
  • RC2 showed a numerically higher immunotherapy response rate, supporting further evaluation of multicellular immune organisation as a candidate biomarker for ICI response.

Molecular subtypes extend beyond population classification

Hepatocellular carcinoma (HCC) displays substantial biological and immunological heterogeneity, contributing to marked differences in response to immune checkpoint inhibitors (ICIs). In an original study published in eGastroenterology, Dr. Budhu from the National Institutes of Health and colleagues investigated whether molecular differences observed across population groups could reveal clinically relevant tumour biology.

The study analysed 46 patients with HCC from the NCI-CLARITY cohort who received ICI-based therapy. Transcriptomic profiling initially identified 126 genes differentially expressed between African American and non-African American patients. However, unsupervised clustering based on these genes generated two molecular subtypes, RC1 and RC2, that were not significantly associated with racial classification, indicating that the resulting clusters reflected tumour-intrinsic molecular heterogeneity rather than population categories alone.

Validation across independent HCC cohorts further showed that most of the more stringently selected genes displayed tumour-specific expression patterns, supporting their relevance to malignant biology rather than constitutional differences.

Distinct tumour-immune environments define RC1 and RC2

Functional analyses demonstrated substantial differences in immune activity between the subtypes. RC2 was enriched for interferon-γ response, inflammatory response and other immune-related pathways, whereas RC1 showed greater enrichment of proliferative programmes, including MYC-related signalling.

These differences were not explained by overall genomic instability. Tumour mutation burden and major nucleotide substitution patterns were similar between RC1 and RC2, suggesting that their divergent immune phenotypes were more closely related to transcriptional and microenvironmental organisation than to global mutational differences.

Immune-cell deconvolution provided a clearer distinction. RC2 tumours showed substantially greater plasma-cell abundance and higher CD8+ T-cell infiltration. Plasma cells and CD8+ T cells were also positively correlated within RC2, whereas RC1 instead showed a strong association between regulatory T cells and M0 macrophages, consistent with a more immunosuppressive microenvironment.

Importantly, RC2 also demonstrated significantly higher tertiary lymphoid structure (TLS) scores using two independent gene signatures. These findings suggest that plasma-cell and CD8+ T-cell enrichment may form part of a broader organised adaptive immune response rather than represent isolated changes in individual immune-cell populations.

Potential relevance to immunotherapy response

The immune-enriched phenotype was accompanied by a higher numerical objective response rate to ICIs: 22.2% in RC2 versus 7.1% in RC1. However, this difference did not reach statistical significance (p=0.150), and the findings should therefore be regarded as hypothesis-generating rather than definitive evidence of predictive value.

An independent spatial transcriptomic dataset from HCC treated with neoadjuvant cabozantinib plus nivolumab provided additional directional support. Responders showed trends towards greater plasma-cell signatures, plasma/CD8 co-high regions and stronger plasma cell–CD8+ T-cell correlations, although the small validation cohort limited statistical power.

Implications for biomarker development

The study advances the concept that the organisation of the tumour immune microenvironment may be more informative than measuring individual immune-cell populations in isolation. A combined signature incorporating plasma cells, CD8+ T cells and TLS features could potentially complement existing HCC immunotherapy biomarkers.

Future prospective studies will be required to determine whether this phenotype is specifically predictive of ICI benefit or primarily reflects favourable tumour biology. Validation in larger, treatment-defined cohorts and integration with spatial profiling, multiplex immunohistochemistry and digital pathology could ultimately facilitate development of a clinically applicable composite immune biomarker.

 

See the articles

Neupane A, Budhu A, Mehrabadi FR, et al. Plasma cell-CD8+ T cell co-enrichment distinguishes immunotherapy-responsive hepatocellular carcinoma subtypes. eGastroenterology 2026;4:e100423. doi:10.1136/ egastro-2026-100423

 

About eGastroenterology

eGastroenterology, a BMJ journal partnered with Gut and launched by leading scientists in gastroenterology and hepatology, has been indexed in the Web of Science Core Collection (ESCI), PubMed, DOAJ, Scopus, CAS, ROAD, and many other major international databases within just two years of its launch.

eGastroenterology has recently received its first Journal Impact Factor of 10.5 and now ranks 11/153 in the Web of Science Gastroenterology & Hepatology category.

For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).

Sign-up to Email Alerts for eGastroenterology: https://emails.bmj.com/k/Bmj/jausu/egastroenterology


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.